Bora CDMO Bora CDMO

X

Find Radio Compass News for Lucitanib

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

https://www.businesswire.com/news/home/20200805005359/en

BUSINESSWIRE
04 Aug 2020

https://www.prnewswire.com/news-releases/new-preclinical-data-on-alks-4230-in-combination-with-lucitanib-to-be-presented-at-2020-american-association-for-cancer-research-aacr-virtual-annual-meeting-ii-301080515.html

PRNEWSWIRE
22 Jun 2020

https://www.businesswire.com/news/home/20200617005130/en

BUSINESSWIRE
17 Jun 2020

https://www.biopharmadive.com/news/meet-the-protein-responsible-for-nearly-100b-in-cancer-drug-deals/561097/

Jacob Bell BIOPHARMADIVE
17 Aug 2019

https://www.businesswire.com/news/home/20190402005328/en/Clovis-Oncology-Announces-Interim-Results-Rubraca%C2%AE-rucaparib/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==

BUSINESSWIRE
02 Apr 2019

https://www.fiercebiotech.com/biotech/clovis-loses-servier-pact-agrees-to-settle-sec-case

Nick Paul Taylor FIERCE BIOTECH
02 Aug 2018
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY